Giuseppe Saglio, MD of the University of Turin, Turin, Italy discusses the pros and cons of chronic myeloid leukemia (CML) first-line therapy, including imatinib, nilotinib and dasatinib. Prof Saglio mentions that trials indicate that higher doses of imatinib may be beneficial for patients. There are higher toxicity levels in 2nd generation tyrosine kinase inhibitors (TKI), such as nilotinib and dasatinib, which include an increased risk of cardiovascular events. However, a deeper molecular response is observed with these drugs. Prof Saglio further discusses the goals that need to be achieved for specific patients and that the more treatments are available, the easier it is to adapt them to each patient’s requirements. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.